Qingtai Su

482 total citations
19 papers, 353 citations indexed

About

Qingtai Su is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Qingtai Su has authored 19 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Immunology and 5 papers in Oncology. Recurrent topics in Qingtai Su's work include Cancer Research and Treatments (5 papers), Immunotherapy and Immune Responses (5 papers) and Developmental Biology and Gene Regulation (4 papers). Qingtai Su is often cited by papers focused on Cancer Research and Treatments (5 papers), Immunotherapy and Immune Responses (5 papers) and Developmental Biology and Gene Regulation (4 papers). Qingtai Su collaborates with scholars based in United States, Switzerland and France. Qingtai Su's co-authors include Xin Li, Michael Ittmann, Botond Z. Igyártó, Chad J. Creighton, Xin Li, Joseph M. Valdez, Li Zhang, Yiqun Zhang, Olga Dakhova and Boyu Zhang and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Qingtai Su

18 papers receiving 351 citations

Peers

Qingtai Su
Yuanlin Wu China
Susan K. Rathe United States
Xiaojian Zhu China
Jingcui Yu China
Mary E. Awad United States
Ruifang Mi China
Jianqi Wu China
Candice Perry United States
Xiaosong Chen China
Tenny Mudianto United States
Yuanlin Wu China
Qingtai Su
Citations per year, relative to Qingtai Su Qingtai Su (= 1×) peers Yuanlin Wu

Countries citing papers authored by Qingtai Su

Since Specialization
Citations

This map shows the geographic impact of Qingtai Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingtai Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingtai Su more than expected).

Fields of papers citing papers by Qingtai Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingtai Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingtai Su. The network helps show where Qingtai Su may publish in the future.

Co-authorship network of co-authors of Qingtai Su

This figure shows the co-authorship network connecting the top 25 collaborators of Qingtai Su. A scholar is included among the top collaborators of Qingtai Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingtai Su. Qingtai Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Su, Qingtai, Stephen Gutowski, Gaurav Bharadwaj, et al.. (2023). Abstract 815: Improved tolerability and tumor specific delivery of a therapeutic bispecific T cell engager using a pH-sensitive nanoparticle platform. Cancer Research. 83(7_Supplement). 815–815. 1 indexed citations
2.
Su, Qingtai, Stephen Gutowski, Austin Burcham, et al.. (2023). 1147-B Encapsulation of IL-12 with an ultra pH-sensitive tumor delivery platform improves tolerability and promotes antitumor response in a preclinical model. SHILAP Revista de lepidopterología. A1836–A1836. 1 indexed citations
3.
Li, Suxin, Min Luo, Zhaohui Wang, et al.. (2022). Abstract P049: ONM-501 ― A synthetic polyvalent STING agonist for cancer immunotherapy. Cancer Immunology Research. 10(1_Supplement). P049–P049. 5 indexed citations
4.
Li, Suxin, Jian Wang, Jonathan Wilhelm, et al.. (2022). Abstract 4234: ONM-501: A polyvalent STING agonist for oncology immunotherapy. Cancer Research. 82(12_Supplement). 4234–4234. 5 indexed citations
5.
Chen, Zirong, Jason Miller, Wei Li, et al.. (2022). 1155 ONM-501, a polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates. Regular and Young Investigator Award Abstracts. A1198–A1198. 3 indexed citations
6.
Gutowski, Stephen, Qingtai Su, Austin Burcham, et al.. (2022). 1200 A clinically validated pH-sensitive nanomedicine platform for encapsulating therapeutic bispecific T cell engagers for tumor specific delivery and activation. Regular and Young Investigator Award Abstracts. A1244–A1244. 1 indexed citations
7.
Bharadwaj, Gaurav, Qingtai Su, Stephen Gutowski, et al.. (2022). Abstract 1734: Encapsulating therapeutic antibodies for tumor specific activation and delivery using a clinically validated pH-sensitive nanoparticle platform. Cancer Research. 82(12_Supplement). 1734–1734. 1 indexed citations
8.
Su, Qingtai, Aurélie Bouteau, Jacob Cardenas, et al.. (2020). Brief communication: Long-term absence of Langerhans cells alters the gene expression profile of keratinocytes and dendritic epidermal T cells. PLoS ONE. 15(1). e0223397–e0223397. 8 indexed citations
9.
Ding, Xinliang, Jason Miller, Qingtai Su, et al.. (2020). 574 ONM-400, a novel approach for interleukin-2 therapy using a ph-activated nanoparticle targeting metabolic acidosis in solid cancers. SHILAP Revista de lepidopterología. A345.1–A345. 2 indexed citations
10.
Lei, Ming, Ahmed Hassan, Qingtai Su, et al.. (2020). Abstract 5195: NBL-015, a next-generation fully human anti-claudin 18.2 antibody with enhanced ADCC and CDC for treating gastric and pancreatic cancers. Cancer Research. 80(16_Supplement). 5195–5195. 2 indexed citations
11.
Su, Qingtai & Botond Z. Igyártó. (2019). Keratinocytes Share Gene Expression Fingerprint with Epidermal Langerhans Cells via mRNA Transfer. Journal of Investigative Dermatology. 139(11). 2313–2323.e8. 27 indexed citations
12.
Bouteau, Aurélie, Qingtai Su, Sandra Zurawski, et al.. (2019). DC Subsets Regulate Humoral Immune Responses by Supporting the Differentiation of Distinct Tfh Cells. Frontiers in Immunology. 10. 1134–1134. 29 indexed citations
13.
Su, Qingtai & Botond Z. Igyártó. (2019). One-step artificial antigen presenting cell-based vaccines induce potent effector CD8 T cell responses. Scientific Reports. 9(1). 18949–18949. 9 indexed citations
14.
Su, Qingtai, et al.. (2018). Novel cyclin D1-based DC vaccine inhibits TNBC tumor growth. The Journal of Immunology. 200(Supplement_1). 181.13–181.13. 2 indexed citations
15.
Kwon, Oh-Joon, Li Zhang, Jianghua Wang, et al.. (2016). Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. Journal of Clinical Investigation. 126(7). 2626–2641. 56 indexed citations
16.
17.
Su, Qingtai & Xin Li. (2016). Notch signaling in prostate cancer: refining a therapeutic opportunity.. PubMed. 31(2). 149–57. 33 indexed citations
18.
Valdez, Joseph M., Li Zhang, Boyu Zhang, et al.. (2014). Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. Nature Communications. 5(1). 4416–4416. 67 indexed citations
19.
Valdez, Joseph M., Li Zhang, Qingtai Su, et al.. (2012). Notch and TGFβ Form a Reciprocal Positive Regulatory Loop that Suppresses Murine Prostate Basal Stem/Progenitor Cell Activity. Cell stem cell. 11(5). 676–688. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuanlin Wu Breakdown of academic impact, for papers by Susan K. Rathe Breakdown of academic impact, for papers by Xiaojian Zhu Breakdown of academic impact, for papers by Jingcui Yu Breakdown of academic impact, for papers by Mary E. Awad Breakdown of academic impact, for papers by Ruifang Mi Breakdown of academic impact, for papers by Jianqi Wu Breakdown of academic impact, for papers by Candice Perry Breakdown of academic impact, for papers by Xiaosong Chen Breakdown of academic impact, for papers by Tenny Mudianto
Rankless by CCL
2026